Roche to Invest 3 Billion Swiss Francs on Basel Site

Roche has today announced new plans to spend 3 billion Swiss francs on upgrading and constructing new labs in Basel, Switzerland. Roche have put the plans forward to invest in creating modern, sustainable workplaces for their employees based in their site in Basel, Switzerland, creating new state-of-the-art offices. The plans include the construction of a

Continue Reading

Avastin receives another NICE rejection

Avastin will still not be financed by the NHS for ovarian cancer after NICE rejected their latest request for approval. In the latest round of draft guidance, the regulatory body confirmed that Roche’s Avastin (bevacizumab) has not been recommended as a NHS treatment for a type of recurrent, advanced ovarian cancer.

Continue Reading

NICE Requests Further Information on Zelboraf

The National Institute for Health and Clinical Excellence (NICE) has issued a second draft guidance to Roche asking them to provide additional information on the use of their skin cancer drug, Zelboraf (vemurafenib). The request concerns Zelboraf’s use in the treatment of unresectable locally-advanced or metatastic BRAF V600 mutation-positive melanoma, for which NICE announced, in

Continue Reading

Roche’s Updated Bid Rejected by Illumina

Illumina’s board of directors unanimously rejected Roche’s revived takeover bid yesterday, describing it as “opportunistic”. Last week, the Swiss major improved their offer by 15% to $51.00 per share, valuing Illumina at around $6.60 billion.  However, after “careful review and consideration together with its financial and legal advisors”, Illumina’s board have not been persuaded. In

Continue Reading

NICE Issues Final Draft Approval For Incivo

The UK’s National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance recommending Janssen Cilag’s Incivo (telaprevir), in combination with Roche’s peginterferon alfa and ribavirin, as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease. The final draft guidance recommends the drug as an

Continue Reading

US FTC Asks For More Information Regarding Roche’s Illumina Takeover Bid

The U.S. Federal Trade Commission (FTC) has asked Swiss pharmaceutical company, Roche, for more information concerning the $5.7 billion hostile takeover proposal for diagnostics company Illumina Inc. Illumina, which is based in San Diego, makes systems that analyse an individual’s DNA.  It is expected that future breakthroughs will use the information to modify treatments in

Continue Reading